Early Comparison of Major Bleeding, Stroke and Associated Medical Costs Among Treatment-Naive Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin

Alpesh, AKeshishian, AXie, LBaşer, OnurPrice, KVo, LSingh, PBruno, AMardekian, JTan, WSinghal, SPatel, COdell, KTrocio J.2019-02-282019-02-282019-02-282019-02-282015Alpesh AN, Keshishian A, Xie L, Baser O, Price K, Vo L, Singh P, Bruno A, Mardekian J, Tan W, Singhal S, Patel C, Odell K, Trocio J. ( December 5-8, 2015). Early comparison of major bleeding, stroke and associated medical costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban or warfarin. American Society of Hematology (ASH) Annual Meeting and Exposition. Orlando. [oral presentation]https://hdl.handle.net/20.500.11779/844Onur Başer (MEF Author)##nofulltext##...eninfo:eu-repo/semantics/closedAccessEarly Comparison of Major Bleeding, Stroke and Associated Medical Costs Among Treatment-Naive Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or WarfarinConference Object